1. Volume 15, Issue 6, Pages 631-639 (May 2014)
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial 
Harpreet Wasan, MD, Dr Angela M Meade, DPhil, Richard Adams, MD, Richard Wilson, MD, Cheryl Pugh, BSc, David Fisher, MSc, Benjamin Sydes, Ayman Madi, MD, Bruce Sizer, MB, Charles Lowdell, FRCP, Gary Middleton, MD, Rachel Butler, BSc, Prof Richard Kaplan, MD, Prof Tim Maughan, MD 
The Lancet Oncology 
Volume 15, Issue 6, Pages (May 2014)
DOI: /S (14)
Copyright © 2014 Wasan et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial design
Treatment cycles continued until progressive disease (PD) with maximally tolerated treatment, or patient choice. FOLFOX=folinic acid and oxaliplatin followed by bolus and infused fluorouracil.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Wasan et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Trial profile
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Wasan et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3 Kaplan-Meier analyses of failure-free survival
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Wasan et al. Open Access article distributed under the terms of CC BY Terms and Conditions

5. Figure 4 Kaplan-Meier analyses of overall survival
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Wasan et al. Open Access article distributed under the terms of CC BY Terms and Conditions

6. Figure 5
Kaplan-Meier analyses of progression-free survival during the chemotherapy-free interval
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Wasan et al. Open Access article distributed under the terms of CC BY Terms and Conditions